News for Healthier Living

ASH 2024: Antibody Shows Encouraging Results for Treating High-risk Follicular Lymphoma and Marginal Zone Lymphoma

ASH 2024 Presentations: Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers - follicular lymphoma and marginal zone lymphoma.

December 8, 2024


December 30 2024

December 29 2024

December 28 2024

December 27 2024

December 26 2024

December 24 2024

December 23 2024

December 21 2024

December 20 2024

December 19 2024

December 18 2024

December 17 2024

December 16 2024